This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: July 13, 2007
Last updated: April 14, 2015
Last verified: April 2015
The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together

Condition Intervention Phase
Overactive Bladder Drug: solabegron and oxybutynin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Repeat Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Solabegron (GW427353) in Combination With Oxybutynin in Healthy Adult Subjects.

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Absorption rate of solabegron and oxybutynin [ Time Frame: as measured by multiple blood draws after repeat dosing ]

Secondary Outcome Measures:
  • To assess bladder function [ Time Frame: prior to dosing Session 1 and post dose for each session ]

Enrollment: 24
Study Start Date: June 2007
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adult males & females ages 18-65;
  • Body weight >50kg; BMI between 19-32;
  • Signed and dated informed consent; QTc Interval <450 msec;

Exclusion Criteria:

  • Resting blood pressure >140/90 mmHg or HR >100 at screening;
  • History of drug allergy or other allergy which, in the opinion of the PI, contraindicates their participation;
  • Positive urine drug, alcohol or serum pregnancy test at screening and prior to dosing;
  • Positive HIV, Hepatitis B, C at screening; use of medications (except acetaminophen)or vitamins or herbal supplements within 7 days or 5 half lives prior to dosing and during study;
  • history of urinary retention, gastric retention, and other sever gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma or who are at risk for these conditions;
  • history of chronic constipation and/or regular laxative use; donation of more than 500mL of blood within 56 days prior to dosing;
  • clinically relevant abnormality identified during screening process or any medical condition or circumstance making the subject unsuitable for participation based on the Investigators assessment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00501267

United States, Washington
GSK Investigational Site
Tacoma, Washington, United States, 98418
Sponsors and Collaborators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

Responsible Party: Study Director, GSK Identifier: NCT00501267     History of Changes
Other Study ID Numbers: B3C109868
Study First Received: July 13, 2007
Last Updated: April 14, 2015

Keywords provided by GlaxoSmithKline:
healthy adults,
drug interaction

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Mandelic Acids
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Urological Agents
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Adrenergic beta-3 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents processed this record on August 21, 2017